Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Deuterabenazine

If you want to know more about the Deuterabenazine, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Deuterabenazine industry. More news about Deuterabenazine, are being released. Follow us / contact us for more Deuterabenazine information!
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    Drug Patent & Exclusivity Expiration Report - Week of Dec 23 2024

    2024-12-23

    This week, there are 4 drugs in the patent and exclusivity list. They are: - STEMLINE THERAPEUTICS INC's ORSERDU, containing active ingredient ELACESTRANT DIHYDROCHLORIDE - ABBVIE INC's UBRELVY, containing active ingredient UBROGEPANT - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's AUSTEDO, containing active ingredient DEUTETRABENAZINE - OTSUKA PHARMACEUTICAL CO LTD's REXULTI, containing active ingredient BREXPIPRAZOLE Read More